-
Massive changes in gene expression and their cause(s) can be a unifying principle in the pathobiology of Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2025-02-06 Paul D. Coleman, Elaine Delvaux, Jeffrey H. Kordower, Ashley Boehringer, Carol J. Huseby
Understanding of the biology of Alzheimer's disease (AD) has long been fragmented, with various investigators concentrating on amyloid beta (Aβ) or tau, inflammation, cell death pathways, misfolded proteins, glia, and more. Yet data from multiple authors has repeatedly shown altered expression of myriad genes related to these seemingly disparate phenomena. In 2022, Morgan et al. organized the massive
-
Differential roles of Alzheimer's disease plasma biomarkers in stepwise biomarker-guided diagnostics Alzheimers Dement. (IF 13.0) Pub Date : 2025-02-05 Hyemin Jang, Daeun Shin, Heejin Yoo, Henrik Zetterberg, Kaj Blennow, Fernando Gonzalez-Ortiz, Nicholas J. Ashton, Theresa A. Day, Eun Hye Lee, Jihwan Yun, Duk L Na, Hee Jin Kim, Sung Hoon Kang, Ko Woon Kim, Si Eun Kim, Yeo Jin Kim, Yeshin Kim, Jaeho Kim, Chi-Hun Kim, Min Young Chun, Na Yeon Jung, Soo Hyun Cho, Jun Pyo Kim, Sang Won Seo
This study aimed to investigate the differential roles of various plasma biomarkers in a stepwise diagnostic strategy for Alzheimer's disease (AD).
-
The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho‐tau Round Robin study Alzheimers Dement. (IF 13.0) Pub Date : 2025-02-05 Nicholas J. Ashton, Ashvini Keshavan, Wagner S. Brum, Ulf Andreasson, Burak Arslan, Mathias Droescher, Stefan Barghorn, Jeroen Vanbrabant, Charlotte Lambrechts, Maxime Van Loo, Erik Stoops, Shweta Iyengar, HaYeun Ji, Xiaomei Xu, Alex Forrest‐Hay, Bingqing Zhang, Yuling Luo, Andreas Jeromin, Manu Vandijck, Nathalie Le Bastard, Hartmuth Kolb, Gallen Triana‐Baltzer, Divya Bali, Shorena Janelidze, Shieh‐Yueh
INTRODUCTIONThe Alzheimer's Association Global Biomarker Standardization Consortium conducted a blinded case–control study to learn which phosphorylated tau (p‐tau) assays provide the largest fold‐changes in Alzheimer's disease (AD) versus non‐AD and show commutability in measuring patient samples and candidate certified reference materials (CRMs).METHODSThirty‐three different p‐tau assays measured
-
The genetic landscape of early‐onset Alzheimer's disease in China Alzheimers Dement. (IF 13.0) Pub Date : 2025-02-05 Wei Qin, Fang‐Yu Li, Wen‐Ying Liu, Ying Li, Shu‐Man Cao, Yi‐Ping Wei, Yan Li, Qi Wang, Qi‐Geng Wang, Jian‐Ping Jia
INTRODUCTIONResearch on somatic and germline mutations in Chinese individuals with early‐onset Alzheimer's disease (EOAD) has been limited.METHODSWe conducted whole‐genome sequencing of blood DNA from 108 patients with EOAD and 116 controls. The analysis included somatic and germline mutations across coding and non‐coding regions, mutational signature determination, pathway enrichment identification
-
Issue Information Alzheimers Dement. (IF 13.0) Pub Date : 2025-02-05
Click on the article title to read more.
-
Soluble Aβ pathology predicts neurodegeneration and cognitive decline independently on p-tau in the earliest Alzheimer's continuum: Evidence across two independent cohorts Alzheimers Dement. (IF 13.0) Pub Date : 2025-02-03 Raffaele Cacciaglia, Carles Falcón, Gonzalo Sánchez Benavides, Anna Brugulat-Serrat, Marta Milà Alomà, Marc Suárez Calvet, José Luis Molinuevo, Karine Fauria, Carolina Minguillón, Gwendlyn Kollmorgen, Clara Quijano-Rubio, Kaj Blennow, Henrik Zetterberg, Luigi Lorenzini, Alle Meije Wink, Silvia Ingala, Frederik Barkhof, Craig W. Ritchie, Juan Domingo Gispert
Identifying the link between early Alzheimer's disease (AD) pathological changes and neurodegeneration in asymptomatic individuals may lead to the discovery of preventive strategies. We assessed longitudinal brain atrophy and cognitive decline as a function of cerebrospinal fluid (CSF) AD biomarkers in two independent cohorts of cognitively unimpaired (CU) individuals.
-
Predicting conversion in cognitively normal and mild cognitive impairment individuals with machine learning: Is the CSF status still relevant? Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-30 Mirella Russo, Davide Nardini, Sara Melchiorre, Consuelo Ciprietti, Gaetano Polito, Miriam Punzi, Fedele Dono, Matteo Santilli, Astrid Thomas, Stefano L. Sensi
Machine learning (ML) helps diagnose the mild cognitive impairment–Alzheimer's disease (MCI-AD) spectrum. However, ML is fed with data unavailable in standard clinical practice. Thus, we tested a novel multi-step ML approach to predict cognitive worsening.
-
The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-29 Daniel Andrews, Simon Ducharme, Howard Chertkow, Maria Pia Sormani, D. Louis Collins
The phase 3 trial CLARITY AD found lecanemab slowed cognitive decline by 27%. However, subgroup analyses indicated a significant 31% sex difference in the effect and suggested no or limited effectiveness in females. We used simulations constrained by the trial design to determine whether that difference reflects a pre-existing sex difference in Alzheimer's disease progression or was a random event
-
Cranial bone maneuver ameliorates Alzheimer's disease pathology via enhancing meningeal lymphatic drainage function Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-30 Xuan Lu, Shanshan Bai, Lu Feng, Xu Yan, Yuejun Lin, Junzhe Huang, Xulin Liao, Haixing Wang, Linlong Li, Zhengmeng Yang, Leo Yik Chun Yan, Boguang Yang, Ming Wang, Jiakang Jin, Zhixian Zong, Zhaowei Jiang, Chuiguo Huang, Chaoran Liu, Xiaoting Zhang, Han Su, Yaofeng Wang, Wayne Yuk‐Wai Lee, Xiaohua Jiang, Micky D. Tortorella, Sien Lin, Ho Ko, Gang Li
INTRODUCTIONAlzheimer's disease (AD) is a progressive neurodegenerative disease and the leading cause of dementia. Recent research highlights meningeal lymphatics as key regulators in neurological diseases, suggesting that enhancing their drainage function could be a potential therapeutic strategy for AD. Our proof‐of‐concept study demonstrated that cranial bone transport can improve meningeal lymphatic
-
Hippocampal neuronal loss and cognitive decline in LATE‐NC and ADNC among community‐dwelling older persons Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-30 Sonal Agrawal, Lei Yu, Sue E. Leurgans, Sukriti Nag, Lisa L Barnes, David A Bennett, Julie A Schneider
INTRODUCTIONThis study investigates the inter‐related roles of hippocampal neuronal loss (HNL), limbic‐predominant age‐related TAR‐DNA binding protein of 43 kDa (TDP‐43) encephalopathy neuropathologic changes (LATE‐NC), and Alzheimer's disease neuropathologic changes (ADNC) on cognitive decline.METHODSParticipants underwent annual cognitive testing and autopsy. HNL, ADNC, LATE‐NC, and other age‐related
-
Biomarker treatment effects in two phase 3 trials of gantenerumab Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-30 Tobias Bittner, Matteo Tonietto, Gregory Klein, Anton Belusov, Vittorio Illiano, Nicola Voyle, Paul Delmar, Marzia A. Scelsi, Susanna Gobbi, Erica Silvestri, Muhamed Barakovic, Antonio Napolitano, Christopher Galli, Maryam Abaei, Kaj Blennow, Frederik Barkhof
INTRODUCTIONWe report biomarker treatment effects in the GRADUATE I and II phase 3 studies of gantenerumab in early Alzheimer's disease (AD).METHODSAmyloid and tau positron emission tomography (PET), volumetric magnetic resonance imaging (vMRI), cerebrospinal fluid (CSF), and plasma biomarkers used to assess gantenerumab treatment related changes on neuropathology, neurodegeneration, and neuroinflammation
-
Dual sensory impairment: Global prevalence, future projections, and its association with cognitive decline Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-30 Brian Sheng Yep Yeo, Esther Yanxin Gao, Benjamin Kye Jyn Tan, Benedict Ding Chao Ong, Ryan Wei Yang Cho, Chee Yit Lim, Ryan Eyn Kidd Man, Eva K. Fenwick, Preeti Gupta, Christopher Li‐Hsian Chen, Samuel Teong Huang Chew, Neville Wei Yang Teo, Song Tar Toh, Jia Hui Ng, Vanessa Yee Jueen Tan, Ecosse L. Lamoureux
There is rising public health concern surrounding dual sensory impairment (DSI), or comorbid hearing and vision impairments. Its global prevalence and the magnitude of its association with cognitive decline (CD) is unclear. Three databases were searched for epidemiological studies examining DSI prevalence or its association with CD. Independent reviewers selected studies, extracted data, and evaluated
-
Plasma proteomic characterization of motoric cognitive risk and mild cognitive impairment Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-30 Gabriela T. Gomez, Sanish Sathyan, Jingsha Chen, Myriam Fornage, Pascal Schlosser, Zhongsheng Peng, Jenifer Cordon, Priya Palta, Kevin J. Sullivan, Adrienne Tin, B. Gwen Windham, Rebecca F. Gottesman, Nir Barzilai, Sofiya Milman, Joe Verghese, Josef Coresh, Keenan A. Walker
INTRODUCTIONMotoric cognitive risk (MCR) is a pre‐dementia syndrome characterized by mobility and cognitive dysfunction. This study conducted a proteome‐wide study of MCR and compared the proteomic signatures of MCR to that of mild cognitive impairment (MCI).METHODSParticipants were classified as MCR using a memory questionnaire and 4‐meter walk. We measured 4877 plasma proteins collected during late‐life
-
Issue Information Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-30
Click on the article title to read more.
-
Plasma p‐tau217 and p‐tau217/Aβ1‐42 are effective biomarkers for identifying CSF‐ and PET imaging‐diagnosed Alzheimer's disease: Insights for research and clinical practice Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-30 Xiaomei Zhong, Qiang Wang, Mingfeng Yang, Gaohong Lin, Kexin Yao, Zhangying Wu, Danyan Xu, Huarong Zhou, Ben Chen, Haishan Shi, Min Zhang, Xiaolei Shi, Yijie Zeng, Jingyi Lao, Shuang Liang, JiaFu Li, Qin Liu, Huanmin Liu, Yunheng Chen, Yicheng Lin, Cong Ouyang, Jieqin Lv, Xiang Liang, Yuwang Cheng, Pengcheng Ran, Baoying Gong, Bin Zhang, Jianwen Guo, Hong Zhang, Sen Liu, Jihui Zhang, Haiying Liu, Yuping
INTRODUCTIONWith the advancement of disease‐modifying therapies for Alzheimer's disease (AD), validating plasma biomarkers against cerebrospinal fluid (CSF) and positron emission tomography (PET) standards is crucial in both research and real‐world settings.METHODSWe measured plasma phosphorylated tau (p‐tau)217, p‐tau181, amyloid beta (Aβ)1‐40, Aβ1‐42, and neurofilament light chain in research and
-
APP antisense oligonucleotides are effective in rescuing mitochondrial phenotypes in human iPSC‐derived trisomy 21 astrocytes Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-29 Srishruthi Thirumalai, Frederick J. Livesey, Rickie Patani, Christy Hung
INTRODUCTIONAntisense oligonucleotides (ASOs) have shown promise in reducing amyloid precursor protein (APP) levels in neurons, but their effects in astrocytes, key contributors to neurodegenerative diseases, remain unclear. This study evaluates the efficacy of APP ASOs in astrocytes derived from an individual with Down syndrome (DS), a population at high risk for Alzheimer's disease (AD).METHODSHuman
-
Iron‐associated lipid peroxidation in Alzheimer's disease is increased in lipid rafts with decreased ferroptosis suppressors, tested by chelation in mice Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-29 Max A. Thorwald, Jose A. Godoy‐Lugo, Gilberto Garcia, Justine Silva, Minhoo Kim, Amy Christensen, Wendy J. Mack, Elizabeth Head, Peggy A. O'Day, Bérénice A. Benayoun, Todd E. Morgan, Christian J. Pike, Ryo Higuchi‐Sanabria, Henry Jay Forman, Caleb E. Finch
INTRODUCTIONIron‐mediated cell death (ferroptosis) is a proposed mechanism of Alzheimer's disease (AD) pathology. While iron is essential for basic biological functions, its reactivity generates oxidants which contribute to cell damage and death.METHODSTo further resolve mechanisms of iron‐mediated toxicity in AD, we analyzed post mortem human brain and ApoEFAD mice.RESULTSAD brains had decreased antioxidant
-
Cross‐cultural validation of plasma p‐tau217 and p‐tau181 as precision biomarkers for amyloid PET positivity: An East Asian study in Taiwan and Korea Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-29 Yung‐Shuan Lin, Hyuk Sung Kwon, Wei‐Ju Lee, Mina Hwang, Jee Hyang Jeong, Seong‐Ho Koh, Seong Hye Choi, Jong‐Ling Fuh
INTRODUCTIONPlasma phosphorylated tau (p‐tau) biomarkers have improved Alzheimer's disease (AD) diagnosis, but data from diverse Asian populations are limited. This study evaluated plasma p‐tau217 and p‐tau181 levels in Korean and Taiwanese populations.METHODSAll participants (n = 270) underwent amyloid positron emission tomography (PET) and blood tests. Plasma p‐tau model‐derived probabilities of
-
Regional brain iron correlates with transcriptional and cellular signatures in Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-29 Aocai Yang, Jixin Luan, Manxi Xu, Lei Du, Kuan Lv, Pianpian Hu, Ni Shu, Zhen Yuan, Amir Shmuel, Guolin Ma
INTRODUCTIONThe link between overload brain iron and transcriptional/cellular signatures in Alzheimer's disease (AD) remains inconclusive.METHODSIron deposition in 41 cortical and subcortical regions of 30 AD patients and 26 healthy controls (HCs) was measured using quantitative susceptibility mapping (QSM). The expression of 15,633 genes was estimated in the same regions using transcriptomic data
-
Variability of cognitive changes after donanemab treatment Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-29 Roger A. L. Dampney
To The Editor In an article in this journal published recently,1 Drs. Daly, Kepp, and Imbimbo discussed the question as to whether the anti-amyloid beta monoclonal antibodies lecanemab and donanemab effectively modify the natural history of disease in patients with early Alzheimer's disease (AD). Based on their analysis of results obtained from two large clinical trials of these drugs carried out over
-
Sleep spindles and slow oscillations predict cognition and biomarkers of neurodegeneration in mild to moderate Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-29 Arsenio Páez, Sam O. Gillman, Shahla Bakian Dogaheh, Anna Carnes, Faride Dakterzada, Ferran Barbé, Thien Thanh Dang‐Vu, Gerard Piñol Ripoll
INTRODUCTIONChanges in sleep physiology can predate cognitive symptoms by decades in persons with Alzheimer's disease (AD), but it remains unclear which sleep characteristics predict cognitive and neurodegenerative changes after AD onset.METHODSUsing data from a prospective cohort of mild to moderate AD (n = 60), we analyzed non‐rapid eye movement sleep spindles and slow oscillations (SOs) at baseline
-
AAIC® Satellite Symposium slated for May 14 to 15 in Lima, Peru Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-28
Hosted in collaboration with the Global Brain Health Institute (GBHI) and the Atlantic Fellows for Equity in Brain Health, the annual Alzheimer's Association International Conference® (AAIC®) Satellite Symposium will take place May 14 to 15 in Lima, Peru, and online. The AAIC Satellite Symposium convenes local and international leaders to discuss brain health and dementia risk; developments in clinical
-
An unsupervised learning approach for clustering joint trajectories of Alzheimer's disease biomarkers: An application to ADNI Data Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-27 Teresa Filshtein Sönmez, Danielle J. Harvey, Laurel A. Beckett
Current models of Alzheimer's disease (AD) progression assume a common pattern and pathology, oversimplifying the heterogeneity of clinical AD.
-
Mediation of modifiable risk factors in two multidomain dementia prevention trials Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-27 Marieke P. Hoevenaar-Blom, Jason Shourik, Jan Willem van Dalen, Willem A. van Gool, Sandrine Andrieu, Edo Richard, Nicola Coley, Eric Moll van Charante,
We explored which dementia risk factors in two multidomain prevention trials mediate beneficial, neutral, or counteracting effects on dementia incidence.
-
Compositional brain scores capture Alzheimer's disease–specific structural brain patterns along the disease continuum Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-27 Patricia Genius, M. Luz Calle, Blanca Rodríguez-Fernández, Carolina Minguillon, Raffaele Cacciaglia, Diego Garrido-Martin, Manel Esteller, Arcadi Navarro, Juan Domingo Gispert, Natalia Vilor-Tejedor,
Traditional multivariate methods for neuroimaging studies overlook the interdependent relationship between brain features. This study addresses this gap by analyzing relative brain volumetric patterns to capture how Alzheimer's disease (AD) and genetics influence brain structure along the disease continuum.
-
A neuropathology case report of a woman with Down syndrome who remained cognitively stable: Implications for resilience to neuropathology Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-27 Jr-Jiun Liou, Jerry Lou, Lisi Flores-Aguilar, Jamie Nakagiri, William Yong, Christy L. Hom, Eric W. Doran, Minodora O. Totoiu, Ira Lott, Mark Mapstone, David B. Keator, Adam M. Brickman, Sierra T. Wright, Brittany Nelson, Florence Lai, Laura Xicota, Lam-Ha T. Dang, Jinghang Li, Tales Santini, Joseph M. Mettenburg, Milos D. Ikonomovic, Julia Kofler, Tamer Ibrahim, Elizabeth Head
Aging adults with Down syndrome (DS) accumulate Alzheimer's disease (AD) neuropathology, including amyloid beta plaques and neurofibrillary tangles, by age 40.
-
A multi-cohort study of longitudinal and cross-sectional Alzheimer's disease biomarkers in cognitively unimpaired older adults Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-27 Long Xie, Sandhitsu R. Das, Yue Li, Laura E. M. Wisse, Emily McGrew, Xueying Lyu, Michael DiCalogero, Ujashi Shah, Ademola Ilesanmi, Amanda E. Denning, Chris A. Brown, Jesse Cohen, Lasya Sreepada, Mengjin Dong, Niyousha Sadeghpour, Pulkit Khandelwal, Ranjit Ittyerah, Sadhana Ravikumar, Shokufeh Sadaghiani, Stanislau Hrybouski, Robin de Flores, Eli Gibson, Paul A. Yushkevich, David A. Wolk
The generalizability of neuroimaging and cognitive biomarkers in their sensitivity to detect preclinical Alzheimer's disease (AD) and power to predict progression in large, multisite cohorts remains unclear.
-
Malnutrition exacerbating neuropsychiatric symptoms on the Alzheimer's continuum is relevant to the cAMP signaling pathway: Human and mouse studies Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-27 Jiwei Jiang, Tianlin Jiang, Xiaohong Wang, Min Zhao, Hanping Shi, Huiying Zhang, Wenyi Li, Shirui Jiang, Xiaoli Zhang, Jiawei Zhou, Qiwei Ren, Linlin Wang, Shiyi Yang, Zeshan Yao, Yaou Liu, Jun Xu
INTRODUCTIONMalnutrition correlates with neuropsychiatric symptoms (NPSs) in Alzheimer's disease (AD); however, the potential mechanism underlying this association remains unclear.METHODSBaseline and longitudinal associations of nutritional status with NPSs were analyzed in 374 patients on the AD continuum and 61 healthy controls. Serum biomarkers, behavioral tests, cerebral neurotransmitters, and
-
Circulating small RNAs shed new light on dementia risk Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-27 Anthony S. Zannas
With populations aging worldwide, dementia has an enormous impact on individuals and societies. Alzheimer's disease (AD), the most common form of dementia, is currently estimated to afflict nearly seven million persons over age 65 in the United States, a number that could double in the coming decades.1 Like every disease, the quest to prevent and treat dementia relies on the discovery of biomarkers
-
Linking higher amyloid beta 1‐38 (Aβ(1‐38)) levels to reduced Alzheimer's disease progression risk Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-27 Luisa Sophie Schneider, Silka Dawn Freiesleben, Gerard van Breukelen, Xiao Wang, Frederic Brosseron, Michael T. Heneka, Stefan Teipel, Luca Kleineidam, Melina Stark, Nina Roy‐Kluth, Michael Wagner, Annika Spottke, Matthias Schmid, Sandra Roeske, Christoph Laske, Matthias H. Munk, Robert Perneczky, Boris‐Stephan Rauchmann, Katharina Buerger, Daniel Janowitz, Emrah Düzel, Wenzel Glanz, Frank Jessen,
INTRODUCTIONThe beneficial effects of amyloid beta 1‐38, or Aβ(1‐38), on Alzheimer's disease (AD) progression in humans in vivo remain controversial. We investigated AD patients' cerebrospinal fluid (CSF) Aβ(1‐38) and AD progression.METHODSCognitive function and diagnostic change were assessed annually for 3 years in 177 Aβ‐positive participants with subjective cognitive decline (SCD), mild cognitive
-
Prevalence of dementia in Singapore: Changes across a decade Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-27 Mythily Subramaniam, Edimansyah Abdin, PV Asharani, Kumarasan Roystonn, Fiona Devi, Wang Peizhi, Saleha Shafie, Vathsala Sagayadevan, Anitha Jeyagurunathan, Boon Yiang Chua, Bernard Tan, Janhavi Ajit Vaingankar, Fengyuan Yao, Harish Magadi, Stefan Ma, Wai Leng Chow, Paul McCrone, Derrick Heng, Rathi Mahendran, Martin Prince, Li Ling Ng, Siow Ann Chong
INTRODUCTIONThe study aimed to assess changes in the prevalence of dementia in Singapore over the past decade.METHODSThe Well‐being of the Singapore Elderly (WiSE) 2023 and the WiSE 2013 studies were comprehensive, single‐phase, cross‐sectional surveys conducted among older adults aged ≥60 years in Singapore. WiSE 2023 included 2010 older adults and 1798 informants, whereas WiSE 2013 comprised 2565
-
Current practices by Alzheimer's Disease Research Centers to remunerate research participants Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-27 Matthew Gabel, Semere Bekena, Mitch O'Meara, Andrea Denny, Erin D. Solomon, Krista L. Moulder, John C. Morris, Jessica Mozersky
INTRODUCTIONRecent guidance from the National Alzheimer's Coordinating Center (NACC) recommends remuneration for all Alzheimer's disease (AD) research participants. Given AD research recruitment challenges, we assessed the remuneration practices at Alzheimer's Disease Research Centers (ADRCs).METHODSWe surveyed 37 ADRCs about remuneration for longitudinal research participants. This included type of
-
Natural language processing‐based classification of early Alzheimer's disease from connected speech Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-27 Helena Balabin, Bastiaan Tamm, Laure Spruyt, Nathalie Dusart, Ines Kabouche, Ella Eycken, Kevin Statz, Steffi De Meyer, Hugo Van Hamme, Patrick Dupont, Marie‐Francine Moens, Rik Vandenberghe
INTRODUCTIONThe automated analysis of connected speech using natural language processing (NLP) emerges as a possible biomarker for Alzheimer's disease (AD). However, it remains unclear which types of connected speech are most sensitive and specific for the detection of AD.METHODSWe applied a language model to automatically transcribed connected speech from 114 Flemish‐speaking individuals to first
-
Response to the Letter, “Circulating small RNAs shed light on dementia risk,” by Anthony S. Zannas Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-27 Andre Fischer, Kwangsik Nho, Andrew J. Saykin, Ivana Delalle
Dear Editor, We are truly grateful for the positive and thoughtful feedback on our recent studies exploring microRNAs (miRNAs) as biomarkers for Alzheimer's disease (AD).1 It is encouraging to see our work recognized for its potential contribution to the field of AD research. We fully agree that replication is crucial. Although our findings highlight promising miRNA signatures, validating these results
-
Identifying gait differences between Alzheimer's disease and dementia with Lewy bodies and their associations with regional amyloid deposition Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-27 Salma Elasfar, Hajr Hameed, Bradley F. Boeve, Julie A. Fields, Clifford R. Jack, Kejal Kantarci, Erik K. St. Louis, Val J. Lowe, Ronald C. Petersen, Farwa Ali, Kaylena Ehgoetz Martens
INTRODUCTIONWe aimed to compare gait between individuals with Alzheimer's disease (AD), dementia with Lewy bodies (DLB), and cognitively unimpaired (CU) individuals and to evaluate the association between gait and regional amyloid beta (Aβ) burden in AD and DLB.METHODSWe included 420 participants (70 AD, 70 DLB, 280 CU) in the Mayo Clinic Study of Aging (MCSA). Gait was assessed using a pressure‐sensor
-
Avoiding causal fraud in the evaluation of clinical benefits of treatments for Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-27 Kathy Y. Liu, Stephen Senn, Robert Howard
Recent regulatory approvals of three amyloid‐lowering monoclonal antibody therapies for the treatment of Alzheimer's disease (AD) have triggered a polarizing debate in the field on the clinical meaningfulness of their reported effects. The question of how to define clinical meaningfulness for any treatment that has a modest effect size is important and will likely be subject to influence from interested
-
The association between adult child education and cognitive functioning among older parents: A cross‐national comparison of diverse contexts Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-27 Emma Nichols, Karla R. Flores Romero, Dipti Govil, Jinkook Lee, Jaqueline M. Torres
INTRODUCTIONThe association between adult child educational attainment and older parent's cognitive health may vary across diverse contexts but cross‐national comparisons have been limited by differences in outcome assessment, study design, and analytic choices.METHODSWe used harmonized data with comprehensive cognitive assessments from the United States (N = 3088), India (N = 3828), and Mexico (N
-
Accelerometer‐measured physical activity timing with incident dementia Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-27 Yuye Ning, Meilin Chen, Hao Yang, Jianping Jia
INTRODUCTIONModerate to vigorous physical activity (MVPA) is linked to lower dementia risk, though the optimal timing remains unclear.METHODSUsing accelerometer‐measured MVPA data from 90,329 dementia‐free UK Biobank participants with at least 2 years of follow‐up, we assessed associations between MVPA patterns (morning, afternoon, evening, mixed, inactive) and dementia risk via multivariable‐adjusted
-
Association of rapid eye movement sleep latency with multimodal biomarkers of Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-27 Jiangli Jin, Jiong Chen, Clémence Cavaillès, Kristine Yaffe, Joseph Winer, Laura Stankeviciute, Brendan P. Lucey, Xiao Zhou, Song Gao, Dantao Peng, Yue Leng
INTRODUCTIONSleep disturbances are associated with Alzheimer's disease (AD) and Alzheimer's disease and related dementias (ADRD), but the relationship between sleep architecture, particularly rapid eye movement (REM) sleep, and AD/ADRD biomarkers remains unclear.METHODSWe enrolled 128 adults (64 with Alzheimer's disease, 41 with mild cognitive impairment [MCI], and 23 with normal cognition [NC]), mean
-
Investing in equitable healthy aging: Why Africa must reform social pension schemes to improve Alzheimer's disease and dementia outcomes Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-27 Cyprian M. Mostert, Najat EL Mekkaoui, Shehzad Ali, Dominic Trepel, Kirti Randcord, Chinedu Udeh‐Momoh, Olivera Nesic, Karen Blackmon, Mary Karanja, Thomas Thesen, David Andai, Rym Ayadi, Harris Eyre, Zul Merali
The eligibility criteria for social pension schemes in Africa hinder equitable and healthy aging. In 2019, women in 14 sub‐Saharan African countries had an average life expectancy of 67 years but a healthy life expectancy of only 57 years, leaving them 5 years in poor health before receiving a pension at age 62. Men had a similar situation—a life expectancy of 62 years and a healthy life expectancy
-
Exploring the role of T cells in Alzheimer's and other neurodegenerative diseases: Emerging therapeutic insights from the T Cells in the Brain symposium Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-27 Wassim Elyaman, Lawrence J. Stern, Ning Jiang, Dallin Dressman, Philip Bradley, David Klatzmann, Elizabeth M. Bradshaw, Donna L. Farber, Sally C. Kent, Shahab Chizari, Kristen Funk, Davangere Devanand, Kiran T. Thakur, Towfique Raj, Osama Al Dalahmah, Rani A. Sarkis, Howard L. Weiner, Neil A. Shneider, Serge Przedborski
This proceedings article summarizes the inaugural “T Cells in the Brain” symposium held at Columbia University. Experts gathered to explore the role of T cells in neurodegenerative diseases. Key topics included characterization of antigen‐specific immune responses, T cell receptor (TCR) repertoire, microbial etiology in Alzheimer's disease (AD), and microglia–T cell crosstalk, with a focus on how T
-
Nutrition: A non‐negligible factor in the pathogenesis and treatment of Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-27 Boye Wen, Xiaodong Han, Jin Gong, Pin Wang, Wenxian Sun, Chang Xu, Aidi Shan, Xin Wang, Heya Luan, Shaoqi Li, Ruina Li, Jinxuan Guo, Runqi Chen, Chuqiao Li, Yao Sun, Sirong Lv, Cuibai Wei
Alzheimer's disease (AD) is a degenerative disease characterized by progressive cognitive dysfunction. The strong link between nutrition and the occurrence and progression of AD pathology has been well documented. Poor nutritional status accelerates AD progress by potentially aggravating amyloid beta (Aβ) and tau deposition, exacerbating oxidative stress response, modulating the microbiota–gut–brain
-
Offspring education and cognitive health: A comparison between Hispanic and White older adults in the United States Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-27 Erika Meza, Karla Renata Flores Romero, Isabel E. Allen, Hector M. González, M. Maria Glymour, Jacqueline M. Torres
INTRODUCTIONWe compared the relationship between offspring education and cognitive health outcomes among Hispanic and White adults.METHODSWe used data from Hispanic and White (1998–2018) United States (US) Health and Retirement Study (HRS) participants (n = 17,484). We assessed cognitive function and decline using episodic memory scores in linear mixed models and incident cognitive impairment with
-
Challenges in multimorbidity and cognitive function studies: A call for rigorous analysis and reporting Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-27 Xiaozhi Chen, Zhiqiang Zhang
This letter is in response to “Multimorbidity measures associated with cognitive function among community-dwelling older Chinese adults” by Wang and colleagues.1 In their article, Wang et al. explored, using longitudinal survey data, the association of multimorbidity with cognitive function among older Chinese adults. We write to highlight key points for further exploration. First, exploratory factor
-
Educational attainment, Aβ, tau, and structural brain reserve in Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-24 Yue Cai, Lili Fang, Anqi Li, Jie Yang, Xin Zhou, Zhengbo He, Pan Sun, Qingyong Wang, Tengfei Guo
Alzheimer's disease (AD) patients with higher educational attainment (EA) often exhibit better cognitive function. However, the relationship among EA status, AD pathology, structural brain reserve, and cognitive decline requires further investigation.
-
Polygenic risk discriminates Lewy body dementia from Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-24 Anna McKeever, Peter Swann, Maura Malpetti, Paul C. Donaghy, Alan Thomas, Elijah Mak, Stephen F. Carter, Jerry H. K. Tan, Young T. Hong, Tim D. Fryer, Amanda Heslegrave, Henrik Zetterberg, Li Su, Leonidas Chouliaras, James B. Rowe, John T. O'Brien
INTRODUCTIONLewy body dementia (LBD) shares genetic risk factors with Alzheimer's disease (AD), including apolipoprotein E (APOE), but is distinguishable at the genome‐wide level. Polygenic risk scores (PRS) may therefore improve diagnostic classification.METHODSWe assessed diagnostic classification using AD‐PRS excluding APOE (AD‐PRSnoAPOE), APOE risk score (APOE‐RS), and plasma phosphorylated tau
-
Hearing and cognitive scores measured with the Montreal Cognitive Assessment Scale in The HUNT Study, Norway Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-23 Christian Myrstad, Bo Lars Engdahl, Sergi Gonzalez Costafreda, Steinar Krokstad, Gill Livingston, Geir Selbæk
-
South Korean study to prevent cognitive impairment and protect brain health through multidomain interventions via face‐to‐face and video communication platforms in mild cognitive impairment (SUPERBRAIN‐MEET): A randomized controlled trial Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-22 So Young Moon, Yoo Kyoung Park, Jee Hyang Jeong, Chang Hyung Hong, Jiwoo Jung, Hae Ri Na, Soo Hyun Cho, Hyun Sook Kim, Hong‐Sun Song, Muncheong Choi, Bon D. Ku, Yeon Sil Moon, Hyun Jeong Han, Yun Jeong Hong, Eun‐Joo Kim, Geon Ha Kim, Ko Woon Kim, Hyemin Jang, Soo Jin Yoon, Hee‐Jin Kim, Seong Hye Choi
INTRODUCTIONWe investigated the efficacy of a multidomain intervention (MI) via face‐to‐face and video communication platforms using a tablet personal computer application in patients with mild cognitive impairment (MCI).METHODSThree hundred participants with MCI and ≥ 1 modifiable dementia risk factor, aged 60‐85 years, were randomly assigned to either the MI group, who underwent a 24‐week intervention
-
Searching for responders to multidomain dementia prevention in late life: A pooled analysis of individual participant data from the MAPT and preDIVA trials Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-17 Nicola Coley, Marieke P. Hoevenaar-Blom, Jason Shourick, Eric P. Moll van Charante, Jan-Willem van Dalen, Willem A. van Gool, Edo Richard, Sandrine Andrieu
It is unknown in which, if any, subgroups of older adults multidomain interventions are effective at reducing long-term dementia incidence.
-
Plasma N-terminal tau fragment is an amyloid-dependent biomarker in Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-17 Guoyu Lan, Laihong Zhang, Anqi Li, Wenqing Ran, Jieqin Lv, Fernando Gonzalez-Ortiz, Yue Cai, Pan Sun, Lin Liu, Jie Yang, Zhengbo He, Lili Fang, Xin Zhou, Yalin Zhu, Zhen Liu, Xuhui Chen, Xiang Fan, Dai Shi, Chenghui Ye, Linsen Xu, Qingyong Wang, Kaj Blennow, Guanxun Cheng, , Pengcheng Ran, Lu Wang, Tengfei Guo
Novel fluid biomarkers for tracking neurodegeneration specific to Alzheimer's disease (AD) are greatly needed.
-
Estimated pulse wave velocity associated with cognitive phenotypes in a rural older population in China: A cohort study Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-17 Jiahui Li, Yifei Ren, Lidan Wang, Xinrui Zou, Xueran Ding, Tingting Hou, Qinghua Zhang, Shi Tang, Xiaojuan Han, Lin Song, Yajun Liang, Yongxiang Wang, Lin Cong, Yifeng Du, Chengxuan Qiu
INTRODUCTIONTo examine the longitudinal association between estimated pulse wave velocity (ePWV) and cognitive phenotypes in a rural Chinese older population.METHODSThis population‐based study included 1857 dementia‐free participants (age ≥60 years) who were examined in 2014 and followed in 2018. ePWV was calculated using age and mean blood pressure (MBP). Cognitive function was assessed using the
-
Long‐range inputome of prefrontal GABAergic interneurons in the Alzheimer's disease mouse Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-17 Miao Ren, Yuxiao Li, Tao Jiang, Bimin Liu, Xuhan Li, Xueyan Jia, Anan Li, Qingming Luo, Hui Gong, Xiangning Li
INTRODUCTIONAlzheimer's disease (AD) is the most common neurodegenerative disease, characterized by damage to cortical circuits. However, the mechanisms underlying AD‐associated changes in long‐range circuits remain poorly understood.METHODSIn this study, we used viral tracing and fluorescence micro‐optical sectioning tomography (fMOST) imaging to investigate whole‐brain changes in the input circuit
-
Usage patterns of cognitive assessments during Medicare's Annual Wellness Visit: A national survey Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-17 Ying Liu, Tabasa Ozawa, Soeren Mattke
INTRODUCTIONMedicare's Annual Wellness Visit (AWV) is a logical opportunity for early detection of cognitive impairment, but recent data for uptake and cognitive assessments during it are lacking.METHODSWe surveyed Medicare beneficiaries of a nationally representative panel about use of AWV and cognitive assessments and analyzed associations between uptake and beneficiaries’ characteristics.RESULTSOf
-
Neural deterioration and compensation in visual short‐term memory among individuals with amnestic mild cognitive impairment Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-17 Ye Xie, Tinghao Zhao, Wei Zhang, Qi Chen, Anqi Qiu, Yunxia Li, Yixuan Ku
INTRODUCTIONVisual short‐term memory (VSTM) is a critical indicator of Alzheimer's disease (AD), but whether its neural substrates could adapt to early disease progression and contribute to cognitive resilience in amnestic mild cognitive impairment (aMCI) has been unclear.METHODSFifty‐five aMCI patients and 68 normal controls (NC) performed a change‐detection task and underwent multimodal neuroimaging
-
Neuron‐derived extracellular vesicles as a liquid biopsy for brain insulin dysregulation in Alzheimer's disease and related disorders Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-17 Jacob Alexander Cleary, Ashish Kumar, Suzanne Craft, Gagan Deep
Extracellular vesicles (EVs) have emerged as novel blood‐based biomarkers for various pathologies. The development of methods to enrich cell‐specific EVs from biofluids has enabled us to monitor difficult‐to‐access organs, such as the brain, in real time without disrupting their function, thus serving as liquid biopsy. Burgeoning evidence indicates that the contents of neuron‐derived EVs (NDEs) in
-
Plasma proteomic biomarkers as mediators or moderators for the association between poor cardiovascular health and white matter microstructural integrity: The UK Biobank study Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-17 May A. Beydoun, Hind A. Beydoun, Nicole Noren Hooten, Zhiguang Li, Yi‐Han Hu, Michael F. Georgescu, Sharmin Hossain, Toshiko Tanaka, Mustapha Bouhrara, Christian A. Maino Vieytes, Marie T. Fanelli‐Kuczmarski, Lenore J. Launer, Michele K. Evans, Alan B. Zonderman
INTRODUCTIONThe plasma proteome's mediating or moderating roles in the association between poor cardiovascular health (CVH) and brain white matter (WM) microstructural integrity are largely unknown.METHODSData from 3953 UK Biobank participants were used (40–70 years, 2006–2010), with a neuroimaging visit between 2014 and 2021. Poor CVH was determined using Life's Essential 8 (LE8) and reversing standardized
-
White matter hyperintensities and TDP‐43 pathology in Alzheimer's disease Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-17 Arenn F. Carlos, Stephen D. Weigand, Nha Trang Thu Pham, Ronald C. Petersen, Clifford R. Jack, Dennis W. Dickson, Jennifer L. Whitwell, Keith A. Josephs
INTRODUCTIONGreater white matter hyperintensities (WMHs) on magnetic resonance imaging (MRI) are seen with transactive response DNA‐binding protein 43 (TDP‐43) pathology in frontotemporal lobar degeneration (FTLD‐TDP). WMH associations with TDP‐43 pathology in Alzheimer's disease (AD‐TDP) remain unclear.METHODSA total of 157 participants from Mayo Clinic Rochester with autopsy‐confirmed AD, known TDP‐43
-
Canadian Stroke Best Practice Recommendations: Vascular cognitive impairment, 7th edition practice guidelines update, 2024 Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-16 Richard H. Swartz, R. Stewart Longman, M. Patrice Lindsay, Rebecca Lund, Aravind Ganesh, Gail A. Eskes, Melissa Austin, Lauren E. Bechard, Jaspreet Bhangu, Venera C. Bruto, Sherri Carter, Nelly Chow, Yan Deschaintre, Kathleen Fedorchuk, Lesley Fellows, Norine Foley, Lee-Anne Greer, Douglas S. Lee, Carol Leonard, Ronak Patel, Sepideh Poonyania, Valerie Poulin, Fatima Quraishi, Pamela Roach, Tricia Shoniker
The Canadian Stroke Best Practice Recommendations (CSPR) 7th edition includes this new module on the diagnosis and management of vascular cognitive impairment (VCI) with or without neurodegenerative disease. An expert writing group and people with VCI lived experience (PWLE) reviewed current evidence. Existing recommendations were reviewed and revised, and new recommendations added. Sections include
-
Virginia Memory Project: Using the Healthy Brain Initiative Roadmap to design a statewide dementia registry Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-16 Annie Rhodes, Ashley Staton, Evan French, Andrea Price, Brian Battle, Catherine MacDonald, Kimberly Ivey, Faika Zanjani, Rachel Coney, Melicent Miller, Meghan Farkas, Lana Sargent, Daniel Bluestein
INTRODUCTIONThe Virginia Memory Project (VMP) is a statewide epidemiological registry for Alzheimer's disease and related disorders (ADRD) and other neurodegenerative conditions. It aims to support dementia research, policy, and care by leveraging the Centers for Disease Control (CDC) Healthy Brain Initiative (HBI) Roadmap.METHODSTo capture comprehensive data, the VMP integrates self‐enrollment and
-
Predicting Alzheimer's disease subtypes and understanding their molecular characteristics in living patients with transcriptomic trajectory profiling Alzheimers Dement. (IF 13.0) Pub Date : 2025-01-15 Xiaoqing Huang, Asha Jacob Jannu, Ziyan Song, Nur Jury-Garfe, Cristian A. Lasagna-Reeves, , Travis S. Johnson, Kun Huang, Jie Zhang
Deciphering the diverse molecular mechanisms in living Alzheimer's disease (AD) patients is a big challenge but is pivotal for disease prognosis and precision medicine development.